Market News

Airbnb stock surges as Q3 earnings top expectations with $4.87B in revenue, an upbeat outlook, and a new $12B buyback program.

Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering an...

2026-11-06. The following slide deck was published by Lincoln National Corporation in conjunction with their 2026 Q3 earnings call.

Cantor Fitzgerald analyst Olivia Brayer Saunders maintains MannKind (NASDAQ:MNKD) with a Overweight and raises the price target from $8 to $10.

Dauch (NYSE:DCH) affirms FY2026 sales outlook from $10.800 billion-$10.875 billion to $10.800 billion-$10.875 billion vs $10.746 billion estimate.

After the last two, the stock rose 24% and then almost doubled. Can it rebound like that again?

TEVA scores 10/10 on ChartMill technical and setup quality, with a breakout entry at $42.11 and exit at $40.66 as trends stay strong.

Dauch (NYSE:DCH) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.18 by 15.79 percent. This is a 37.5 pe...

Array Digital Infr (NYSE:AD) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.45 by 80 percent. This is ...

By Brian Lantier, CFA NASDAQ: MKTW READ THE FULL MKTW RESEARCH REPORT MarketWise’s (NASDAQ: MKTW) third-quarter results showed the power of the compan...

HONG KONG, November 06, 2026--Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988 (HKD Counter) and 89988 (RMB Counter), "Alibaba" or "Alibaba Gr...

Elevated default risks and higher funding costs have contributed to Upstart's impacted loan originations and lowered FY2026 guidance. See more on UPST...

Telephone and Data Systems, Inc. (NYSE:TDS) announced its Board approved incremental $250 million share repurchase authorization. 

Cantor Fitzgerald analyst Gareth Gacetta maintains Hyperliquid Strategies (NASDAQ:PURR) with a Overweight and raises the price target from $34.3 to...

Telephone and Data (NYSE:TDS) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.13 by 100 percent. This i...

Lower diarrhea rates emerge, but toxicity control remains the key test.

Guidance rose as international sales neared a fifth of the business.

Agent Studio launch and a big bank expansion highlight the quarter.

Management reaffirmed its 2028 targets as rising yields test the financing model.

Revenue rose as the company winds down its legacy specialty lending unit.